NUVECTIS PHARMA, INC.

(NASDAQ: NVCT)

 

 

 

Press Releases

10
Dec
2024
Fort Lee, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium. Event2024 Ladenburg Virtual Oncology I...
14
Nov
2024
NXP800 demonstrated single agent activity New dosing schedule successfully minimized thrombocytopenia Fort Lee, NJ, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mu...
First | Previous | Next  | Last

SEC Filings

First   Previous   Next   Last

Stock Information

$5.22
$0.20|3.98%
Bid:$4.91x100 Ask:$5.39x1,000
12/27/2024 4:03 PMET Volume:102,954
|Nasdaq|DELAYED PRICE
Last
$5.22
$Chg
$0.20
Open
$4.88
High
$5.44
MarketCap
$100.855 M
Bid
$4.91
Bid Size
100
Year High
$12.10
PB Ratio
8.82
EPS
$-1.48
Volume
102,954
% Chg
3.98%
Prev. Close
$5.02
Low
$4.85
Shares
19,320,973
Ask
$5.39
Ask Size
1,000
Year Low
$4.44
PE Ratio
-
Exchange
Nasdaq
Dec 27, 2024 4:03 PM ET

Governance